

Ksenia Brusilovskaya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6336016/publications.pdf>

Version: 2024-02-01

9
papers

170
citations

1651377

6
h-index

1637695

9
g-index

9
all docs

9
docs citations

9
times ranked

211
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , 2022, 75, 610-622.	3.6	18
2	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. <i>Platelets</i> , 2022, 33, 879-886.	1.1	5
3	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. <i>Advances in Medical Sciences</i> , 2022, 67, 154-162.	0.9	4
4	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. <i>Biomedicines</i> , 2021, 9, 60.	1.4	37
5	Nuclear receptors in liver fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166235.	1.8	23
6	Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. <i>United European Gastroenterology Journal</i> , 2020, 8, 1174-1185.	1.6	20
7	Vascular Targets for the Treatment of Portal Hypertension. <i>Seminars in Liver Disease</i> , 2019, 39, 483-501.	1.8	19
8	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , 2018, 8, 9372.	1.6	39
9	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	5